Incidence of progressive disease in SSc according to SSc subtype Progressive disease, N (%)
| Total | DcSSc | LcSSc | LSSc | |
|---|---|---|---|---|
| N=171 | N=64 | N=79 | N=28 | |
| Deceased | 8 (5) | 3 (5) | 4 (5) | 1 (4) |
| ≥10% decrease in body weight | 10 (6) | 5 (8) | 2 (3) | 3 (11) |
| ≥30% increase with minimum of Δ5 in MRSS* | 15 (9) | 7 (11) | 7 (9) | 1 (4) |
| ≥30% decrease in eGFR | 6 (4) | 3 (5) | 3 (4) | 0 (0) |
| ≥10% decrease in FVC* | 13 (8) | 3 (5) | 6 (8) | 4 (14) |
| ≥15% decrease in DLCO* | 12 (7) | 5 (8) | 6 (8) | 1 (4) |
| ≥0.25 increase in SHAQ† | 11 (6) | 3 (5) | 8 (10) | 0 (0) |
| Total patients with progressive disease | 63 (37) | 25 (39) | 30 (38) | 8 (29) |
*<5% missing.
†<15% missing.
DcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity for carbon monoxide; eGFR, estimated glomerular filtration rate; FVC, forced vital capacity; LcSSc, limited cutaneous systemic sclerosis; MRSS, modified Rodnan Skin Score; SHAQ, Scleroderma Health Assessment Questionnaire.